Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Key Points
Bristol Myers Squibb’s Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company’s 7% revenue gain to $13.1 billion.
Adjusted EPS fell 17% to $1.35, but mostly because of deal accounting, not a weaker core business.
- Motley Fool Issues Rare "Total Conviction" Buy Alert ›
Bristol Myers Squibb's (NYSE:BMY) Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain. Shares were roughly flat in midday trading. Bristol now grows on its newer medicines. The drop in adjusted earnings reflects the cost of buying its next ones, not a weaker core business.
Key Numbers
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
- Total revenue: $13.1 billion, up 7% from the prior-year quarter
- Growth Portfolio revenue: $7.7 billion, up 12%
- Earnings per share: $1.05 GAAP and $1.35 adjusted, with adjusted down 17% from $1.63
- 2026 revenue guidance: raised to $49.75 billion to $50.25 billion
What It Means
The Growth Portfolio added roughly $830 million in sales from a year ago, about as much as the whole company added. The release credits Opdivo Qvantig, Breyanzi and three other drugs, so growth doesn't hang on a single launch. That breadth is what a company replacing aging blockbusters needs.
The Legacy Portfolio rose 1%, but only because Eliquis outran generic erosion across the older drugs. Eliquis faces its own patent expiration later this decade, so that stability is temporary.
The earnings decline is mostly deal accounting. Acquired IPRD charges are upfront payments for drug candidates licensed from other companies. Net of licensing income, they cost $0.58 a share. The release raises the sales outlook but only "updates" the adjusted EPS range, which now absorbs those charges. Bristol is spending today's earnings to refill its pipeline before Eliquis fades.
What to Watch Next
Track whether the Growth Portfolio holds double-digit growth as Eliquis gains slow. Also watch whether the licensed programs produce data that justifies their price.
Should you buy stock in Bristol Myers Squibb right now?
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $334,308!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,323,413!*
Now, it’s worth noting Stock Advisor’s total average return is 897% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 29, 2026.
David Kretzmann has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.
Recommended Articles
